PARIS: ABL Diagnostics, a molecular diagnostics and healthcare software company listed on Euronext Paris, has been selected by the Évry Commercial Court to acquire the assets and operations of TEXCELL, the company announced.
The court approved ABL Diagnostics’ plan following the submission of an industrial proposal aimed at ensuring business continuity, preserving TEXCELL’s scientific expertise and building on complementary work already underway at ABL Diagnostics in molecular diagnostics, virology and infectious diseases, a statement said.
TEXCELL, which grew out of the Institut Pasteur’s scientific ecosystem, specializes in viral safety, biosafety, genomic analysis, immunological monitoring and services for biotechnology and therapeutic developers. The company generated approximately 5.4 million euros in revenue in 2024, down from 6.2 million euros in 2023 and 7.5 million euros in 2022, according to publicly available financial information.
Under the terms of the deal, ABL Diagnostics will keep TEXCELL’s operations running at the Genopole site in Évry-Courcouronnes and will retain 29 employees, including 23 permanent staff and six apprentices or trainees. The company will also assume accrued employee rights for the transferred workers totaling 91,829.24 euros, subject to final adjustment.
ABL Diagnostics estimated the overall value of the transaction at approximately 2.9 million euros. That figure includes a 225,000-euro purchase price for TEXCELL’s assets — split between 165,000 euros in intangible assets and 60,000 euros in tangible assets — along with a lump-sum inventory purchase of 30,000 euros before tax and the reconstitution of roughly 100,000 euros in security deposits.
The company will also take on lease financing agreements for operational equipment, with future installments totaling 531,792.74 euros, subject to final adjustment. Separately, ABL Diagnostics plans an industrial and technology investment program of about 930,000 euros and expects working capital needs tied to the acquired business to rise by roughly 1 million euros.
The company said the acquisition will be financed using the group’s existing financial resources. Terms of the accepted offer were filed with the Évry Commercial Court as part of the sale process.
ABL Diagnostics said the deal builds on a strategic partnership it recently formed with the Institut Pasteur in Paris on an HPV RNA-sequencing genotyping project, and that TEXCELL’s historical ties to the institute reinforce that scientific direction. The company said TEXCELL’s capabilities in viral safety, biological control, cell culture, viral characterization and biosafety complement its existing UltraGene, DeepChek and Nadis platforms.
The acquisition also gives ABL Diagnostics a physical presence at Genopole Évry-Courcouronnes, a biotechnology research hub. The company said it plans to gradually expand the site’s workforce by hiring about five additional employees to support scientific operations inherited from TEXCELL.
ABL Diagnostics said it intends to continue developing the scientific assets it is acquiring, including characterized virus banks, cell line collections and biosafety infrastructure, which it said could support future tools for biomedical research, biological quality control and molecular diagnostics.
Dr. Chalom Sayada, chief executive officer of ABL Diagnostics, said in a statement that the acquisition brings “recognized scientific expertise, qualified teams, an established international brand” and technological and biological assets that complement the company’s existing operations.
“This transaction is fully aligned with ABL Diagnostics’ long-term strategy to strengthen its position among the leading international players in molecular biology, virology, and infectious diseases,” Sayada said, adding that the company’s growth has combined internal innovation, proprietary technology and targeted acquisitions.
Sayada said the company plans to invest in automation, infrastructure modernization, staffing and scientific development to support laboratories, research centers, biotechnology firms and health care companies worldwide.
The transaction remains subject to standard legal and administrative procedures. ABL Diagnostics said it would provide further details on integrating the acquired operations and its 2026 strategic plans at a later date.
